Compare Amphastar Pharmaceuticals Inc (AMPH) vs TeraWulf Inc (WULF) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

WULF trades at $21.97, down 5.3% today, amid a bearish technical signal. The stock shows extreme valuation ratios with a P/S of 53.26 and P/B of 84.25, while profitability metrics are deeply negative, including a net income margin of -611.46%. Recent news highlights a major $19 billion, 20-year contract with Anthropic for AI data center infrastructure, signaling a strategic pivot but also high capital expenditure requirements.

The outlook is bifurcated: strong analyst buy consensus and the Anthropic deal offer long-term growth potential in AI infrastructure, but near-term risks include persistent losses, high debt, and execution challenges. Investors face volatility from operational cash burn and market sentiment shifts around AI stocks.